Adenosine A3 receptor antag 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
  • ||||||||||  PBF-677 / Palobiofarma
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  ADENOIBD: Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients (clinicaltrials.gov) -  Jan 13, 2022   
    P2a,  N=34, Completed, 
    We introduced the technique suitable for observing A3R expression, small molecule competition monitoring, and confirmation of binding to A3AR of novel compounds even in native conditions. Recruiting --> Completed | N=50 --> 34 | Trial completion date: Oct 2021 --> May 2021 | Trial primary completion date: Aug 2021 --> May 2021
  • ||||||||||  PBF-677 / Palobiofarma
    Trial completion date, Trial primary completion date:  ADENOIBD: Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients (clinicaltrials.gov) -  Sep 19, 2020   
    P2a,  N=50, Recruiting, 
    These findings open a novel therapeutic opportunity in liver cancer with minute CBD concentrations and low content of psychotropic THC fraction . Trial completion date: Dec 2020 --> Oct 2021 | Trial primary completion date: Jun 2020 --> Aug 2021